Advanced Prostate Cancer
Clinical research in advanced prostate cancer with a focus on endocrine control and suppression of disease-driving androgen activity.
- Gonadotropin-releasing hormone (GnRH) antagonists
- Testosterone suppression
- Castration-resistant disease management
Work in this area is centered on hormonal therapy for men with advanced malignancy of the prostate.
Urologic Oncology
The sponsor’s research interest extends to urologic oncology, particularly therapies directed at advanced malignancies affecting the male reproductive system.
- Prostate cancer treatment
- Androgen deprivation
- Hormone-sensitive tumour control
This area reflects a therapeutic emphasis on managing metastatic and hormonally driven disease.
Endocrine Modulation
Research activity includes therapies that alter endocrine signalling to reduce gonadal hormone production and maintain low testosterone levels.
- Pharmacodynamics
- Hormone suppression
- GnRH pathway inhibition
These interests align with treatment strategies designed to control androgen-dependent cancer.
Clinical Pharmacology
The sponsor is also involved in clinical pharmacology research examining how a GnRH antagonist behaves in people with advanced malignancy.
- Pharmacokinetics
- Safety evaluation
- Efficacy assessment
This field supports the development of therapies aimed at sustained androgen suppression in prostate cancer.
